Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Guardion Health Sciences, Inc. (GHSI)
|
Add to portfolio |
|
|
|
| Price: |
$0.69
| | Metrics |
| OS: |
1.27
|
M
| |
|
|
| Market cap: |
$881.2
|
k
| |
|
|
|
Net cash:
|
$8.37
|
M
| |
$6.57
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 7.2 | 1.9 | 0.9 | 0.9 | 0.4 | 0.1 | 0.1 | 0.2 |
| Revenue growth | 282.7% | 109.3% | -4.2% | 115.4% | 210.1% | 25.0% | -31.5% | -36.8% |
| Cost of goods sold | 4.1 | 1.9 | 0.3 | 0.4 | 0.2 | 0.1 | 0.1 | 0.1 |
| Gross profit | 3.1 | -0.1 | 0.6 | 0.5 | 0.3 | 0.1 | 0.1 | 0.0 |
| Gross margin | 43.0% | -3.0% | 62.2% | 57.7% | 59.9% | 46.3% | 55.6% | 11.6% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 2.3 | 1.5 | 1.9 | 1.5 | 0.6 | 0.4 | 0.2 | 0.0 |
| Research and development | 0.1 | 0.2 | 0.2 | 0.2 | 0.3 | 0.0 | 0.4 | 0.0 |
| General and administrative | 11.2 | 7.5 | 7.4 | 4.9 | 4.7 | 3.3 | 5.6 | 0.6 |
| EBITA | -9.9 | -8.5 | -8.9 | -5.9 | -5.2 | -3.9 | -6.4 | -0.7 |
| EBITA margin | -136.8% | -449.9% | -989.4% | -629.3% | -1195.3% | -2797.8% | -5663.2% | -430.9% |
| Amortization of intangibles | 0.7 | | | 0.2 | 0.1 | | | |
| EBIT | -10.6 | -8.5 | -8.9 | -6.1 | -5.3 | -3.9 | -6.4 | -0.7 |
| EBIT margin | -146.4% | -449.9% | -989.4% | -652.1% | -1207.6% | -2797.8% | -5663.2% | -430.9% |
| Pre-tax income | -24.7 | -8.6 | -10.9 | -7.8 | -5.3 | -5.7 | -8.8 | -1.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -24.7 | -8.6 | -10.9 | -7.8 | -6.2 | -6.5 | -8.8 | -1.3 |
| Net margin | -342.1% | -453.6% | -1204.8% | -824.4% | -1421.2% | -4639.8% | -7837.3% | -802.3% |
| |
| Diluted EPS | ($1.04) | ($0.60) | ($1.79) | ($0.38) | ($0.45) | ($0.30) | ($0.54) | ($0.12) |
| Shares outstanding (diluted) | 23.7 | 14.3 | 6.1 | 20.2 | 13.9 | 21.8 | 16.4 | 10.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|